all in this issue of Circulation reports that myocardial perfusion is absent in about one fourth of their population of patients with AMI despite reflow being achieved in the occluded vessel within 6 hours of onset of symptoms. In this study, myocardial contrast echocardiography (MCE) was used at the time of emergent cardiac catheterization to assess myocardial perfusion before and 15 minutes after successful reflow to the occluded coronary artery. This is the first published study demonstrating the no reflow phenomenon in patients with AMI using MCE.
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The no reflow phenomenon was first described in the myocardium by Krug et a12 and pathologically characterized by Kloner and colleagues.3 Although the precise mechanism of the no reflow phenomenon has not been clarified,4-7 loss of microvascular integrity remains its hallmark.2 As such, any marker of blood flow to the myocardium can be used to elucidate this phenomenon. MCE uses the direct injection of microbubbles of air into the arterial circulation. As these bubbles pass through the myocardium, they produce contrast enhancement during simultaneously performed two-dimensional echocardiography. MCE has been used successfully in the cardiac catheterization laboratory for the assessment of myocardial perfusion.8-10 It adds but a few minutes to coronary angiography and has been proven to be safe in patients. 1, [8] [9] [10] In their article, Ito and colleagues have reported that the patients showing the no-reflow phenomenon had poor regional and global left ventricular function 1 month after successful reflow to the infarct-related artery compared with those who did not demonstrate this finding.1 Why is this so? Kloner3 and others11 '12 have shown that regions with no reflow are associated with more extensive myocardial necrosis in the dog.
Another study by Kloner and colleagues also suggests that myocellular necrosis may precede microvascular damage, and that the latter may be a predictor of infarction.13 It is, therefore, probable that the presence of no reflow in the study by Ito and colleagues identified patients with larger infarcts and hence, those least likely to demonstrate myocardial salvage. In a study from our laboratory in which flow was established within an occluded vessel several days after an AMI, patients with no reflow on MCE had the largest infarcts by cardiac enzymes.14 In a study using a canine model of coronary occlusion followed by reperfusion, Kemper and colleagues first suggested the possibility of using MCE to define the success of reperfusion.15 These authors demonstrated that when contrast was injected into the aortic root during coronary occlusion, the MCE-defined risk area correlated well with that defined on postmortem technetium autoradiography. After the occlusion was reversed and contrast was reinjected into the aortic root, the myocardial contrast defect correlated well with infarct size. In preliminary studies, similar results have been observed in our laboratory from both left16 and right atrial17 injection of contrast. MCE, therefore, offers the unique opportunity of defining in vivo the risk area during acute coronary occlusion and infarct size after reperfusion.
A limitation of the study by Ito and colleagues is that they defined risk area in the apical two-chamber view using only left main coronary artery injection of contrast. As such, right-to-left collaterals were not demonstrated during MCE by using their method, and hence, the functional risk area was likely overestimated. We have shown that most MCE-defined collateral flow to the occluded left anterior descending coronary artery bed in patients with coronary artery disease comes from the right coronary artery and that MCE is superior to coronary angiography in defining collateral flow.14 Because some degree of perfusion is maintained during coronary occlusion to regions supplied by collateral flow, these regions escape the extreme ravages of ischemia and hence do not demonstrate the no reflow phenomenon after successful reperfusion. ' 
